| Literature DB >> 32038054 |
Nasrin Abolhasanpour1, Sakineh Hajebrahimi2,3, Abbas Ebrahimi-Kalan4, Ahmad Mehdipour5, Hanieh Salehi-Pourmehr2,6.
Abstract
Neurogenic bladder (NGB) secondary to spinal cord injury (SCI) is accompanied with several complications such as urinary tract deterioration, urinary incontinence, and consequently lower quality of life (QoL), significant morbidities, and occasionally death. Current therapeutic methods have some side effects and there is no treatment for the upper urinary tract injuries. Stem cell therapy is a promising method for treating this condition. However, the best timing and the best route of its transplantation have not yet been determined. Animal models of SCI, especially in rats, are the most commonly used method for evaluating the efficacy of cell therapy in NGB improvement, and the most common assessment method is the urodynamic studies (UDS). However, there are variations in the range of UDS parameters among the published studies. The current review aimed to discuss the effect of stem cell transplantation on bladder dysfunction recovery based on urodynamic parameters after SCI in rats. For this purpose, the cell source, doses, the route of administration, and the complete UDS equipment and its parameters were summarized in SCI models in rats. In some urodynamic test results, to some extent, an improvement in the lower urinary system function was observed in each treatment group. However, this improvement was far from full functional recovery. The average cell dose was about 1 million cells in every injected site. In most studies, the stem cells (SCs) were transplanted 9 days after the injury using PE-50 and PE-60. Many researchers have recommended further experimental and clinical studies to confirm this treatment modality. Copyright: © Shiraz University of Medical Sciences.Entities:
Keywords: Neurogenic; Spinal cord injuries; Stem cell transplantation; Urinary bladder; Urodynamic
Year: 2020 PMID: 32038054 PMCID: PMC6983271 DOI: 10.30476/ijms.2019.45318
Source DB: PubMed Journal: Iran J Med Sci ISSN: 0253-0716
Characteristic of SCI and stem cell types in the reviewed studies
| Reference | SCI type | Device name for injury | The number of rodents in each group | Cell type for transplantation | Cell labeling | Time of transplantation after SCI | Route of transplantation | Cell count | Injured vertebrate segment |
|---|---|---|---|---|---|---|---|---|---|
| Cho[ | Needle-stick injury | 22-gauge needle | 10 | Oral mucosa stem cells | Just after SCI | Stem cells were infused over the course of 1 min by using a 22-gauge insert vein (IV) catheter intrathecal | 100 μl | T11 | |
| Park[ | Contusion | Multicenter animal SCI study (MASCIS) impactor (Rutgers, The State University of New Jersey, Newark, NJ), a 10-gram rod was dropped from a vertical distance of 25 mm | 6-11 | hMSCs | 9 days after injury | Into the injured spinal cord via Hamilton syringe | 5 μL | T9 | |
| Obara[ | Compression | Compression with a 40-gram rod (tip area: 3.0-2.2 mm) placed on the exposed dura for 30 minutes | 5 and 15 | BAM grafting | 2 to 3 weeks after BAM grafting | A BAM was firmly anastomosed to the host bladder with running and interlocking 7-0 absorbable sutures. | T10 | ||
| Sander[ | Contusion | Infinite Horizon (IH) impactor SCI device (Precision Systems and Instrumentation, Lexington, KY, USA) with an impact force of 200 kilodynes (kdyn) | 6-8 | BMSCs | 3 days postinjury | Into the center of the lesion at a maximum depth of 1.5 mm using a pulled glass pipette (100 μm internal diameter) and a Picospritzer II | 1×105 | T9 | |
| Urakami[ | Transection | Micro scissors | BAM grafting | 8 weeks after SCI (bladder replacement) | The BAMG was anastomosed to the host bladder with running and interlocking 7–0 absorbable sutures | T10 | |||
| Temeltas[ | Hemisection | Micro scissors | 6-10 | NRP/GRP | 9 days after hemisection | Into the injury cavity | 1×106 | T9-T10 | |
| JIN[ | Contusion | NYU impactor (10 g, 25 mm) | 9-10 | NPCs | 13 weeks after SCI | Using a 10-ul NanoFil syringe with a 33-gauge needle, 1×105 cell/µl were injected into the lesion center along the midline (4 µl) and rostral and caudal to the lesion along the midline (3 µl/each). | T10 | ||
| Lee[ | Contusion | Chung-Ang University Hospital Model 2.0 (CAUH-2) pneumatic impactor (3 mm depth) | 10 | BM3.B10 |
| 4 weeks after SCI | Into the bladder muscle of the rats in six areas | 1×106 | T9 |
BAM: Bladder acellular matrix; hMSCs: Human mesenchymal stem cells; BMSCs: Bone marrow stromal cells; NRP: Neuronal restricted precursors; GRP: Glial restricted precursors
Characteristic of UDS in the reviewed studies
| Reference | The time of cystometry after bladder catheterization | Time of catheterization to perform cystometry after SCI | The type of catheter used for cystometry | Animals status in cystometry (conscious or anesthetized) | The type of anesthetic drug for catheterization | Cystometry set-up | The rate of infusion into bladder |
|---|---|---|---|---|---|---|---|
| Cho[ | Just before cystometry | 21 days after SCI | PE-50 | Anesthetized | Zoletil | Pressure transducer and a syringe pump (Harvard Apparatus, Holliston, MA, USA) monitored using LabScribe (iWork System, Inc., Dover, NH, USA). | 0.50 ml/min |
| Park[ | Just before cystometry | 28 and 56 days after injury | Double lumen polyethylene catheter (PE-160 and PE-50; Clay Adams, Parsippany, NJ, USA) | anesthetized | Isoflurane | Pressure transducer by polygraph (Grass polygraph model 7E, Quincy, MA, USA) and infusion pump (Baxter, Deerfield, IL, USA). | First 10 ml/hour and then 5 ml/hour |
| Obara[ | Just before cystometry | 5, 7, and 15 weeks after SCI | PE-60 (Clay Adams, Parsippany, NJ, USA) | Anesthetized | Pentobarbital sodium | Pressure transducers (Statham P-23, Gulton-Statham Transducers, CA, USA) and recorded by (Menuet Compact, Dantec Medical A/S, Denmark). | 0.10 ml/min |
| Sander[ | 3 to 4 days prior to urodynamic measurements | 8.5 weeks post injury | PE catheter (diameter 2.1 mm, PE-50 (Schubert Medizinprodukte, Wackersdorf, Germany) | Conscious | Ketamine, xylazine, and acepromazine | Force transducer (MLT1030/D wide range force transducer; AD Instruments, Oxford, UK), pressure transducer (MLT0699 disposable BP transducer; AD Instruments, New Zealand) and to a syringe pump (KR Analytical, Cheshire, UK), data acquisition system (PowerLab 8/35; AD Instruments, New Zealand) | 6 ml/h |
| Urakami[ | Just before cystometry | Before grafting, 8 and 16 weeks after SCI and bladder replacement | 22-gauge catheter | Anesthetized | Ketamine | 0.20 ml/min | |
| Temeltas[ | 4 to 6 hours after recovery | 4 weeks after transplantation | PE-50 | ketamine+xylazine | Biopac Systems™ device | 0.20 ml/min | |
| JIN[ | 1-2 hour before urodynamic measurements | 22 weeks after SCI and 8 weeks after transplantation | PE-60 (Clay Adams, Parsippany, NJ, USA) | Conscious | Isoflurane | Pressure transducer (BLPR; World Precision Instruments) (BLPR; Bladder pressure transducer, Germany) and infusion pump (STC-523; Terumo, Tokyo, Japan) | 0.10 ml/min |
| Lee[ | 5-6 hour before urodynamic measurements | 4 weeks after cell transplantation and 8 weeks after injury | PE-50 (Harvard Clinical Technology, Inc., South Natick, MA, USA) | Conscious | Isoflurane | 0.04 ml/min |
PE: Polyethylene tube
Measured urodynamic parameters in SCI-induced neurogenic bladder in the reviewed studies
| Reference | Groups | Contraction pressure (cmH2O) (mean±SD) | Contraction time (seconds) (mean±SD) | Voiding pressure (mean±SD) | Voided volume (mean±SD) | Voiding frequency (time/min) (mean±SD) | Maximal pressure (mean±SD) | Voiding pressure (VP) (mean±SD) | Pressure threshold (PT) (mean±SD) | Bladder capacity (mean±SD) | Bladder compliance (mean±SD) | Post-void residual volume (mean±SD) | Baseline pressure (cmH2O) (mean±SD) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cho[ | Control | 2.55±0.22 | 8.09±0.43 | ||||||||||
| Negative control | 6.49±0.77 | 15.29±1.65 | |||||||||||
| Experimental |
|
| |||||||||||
| Park[ | Control 1 PBS (n=7) | 0.80±0.09 | 9.21±5.30 | 1345.25±1206.27 mm3 | |||||||||
| Control 2 hFb (n=11) | 0.82±0.16 | 9.60±4.20 | 1263.75±838.05 mm3 | ||||||||||
| Experimental hMSC (n=9) | 0.76±0.32 | 9.70±4.11 | 1279.57±1310.69 mm3 | ||||||||||
| Lee[ | Control | 39.24±2.64 | 8.18±0.77 | ||||||||||
| Sham | 43.77±1.50 | 8.50±0.54 | |||||||||||
| SCI | 77.73±2.64 | 7.13±0.72 | |||||||||||
| SCI+B10 | 57.35±4.15 | 8.54±0.31 | |||||||||||
|
| SCI | 23.00±2.25 | 72.60±9.56 | 26.38±6.38 | |||||||||
| BMSC-grafted | 19.75±1.87 | 81.73±9.13 | 29.36±3.82 | ||||||||||
| Fibroblast-grafted | 15.50±1.12 | 65.65±6.52 | 19.57±2.55 | ||||||||||
| Urakam[ | Control | 0.50±0.10 | |||||||||||
| Before graft | 0.37±0.07 | 1.38±0.20 | |||||||||||
| After BAM-grafted |
| ||||||||||||
| Temeltas[ | Sham | 24.90±4.03 | 0.56 | 24.90 | 0.57±0.13 | 0.05±0.07 | 2.15±0.54 | ||||||
| SCI+neuronal restricted precursor/glial restricted precursor |
| 1.02 |
|
|
| 3.38±0.30 | |||||||
| SCI+BM-SCs |
| 0.90 |
|
|
|
| |||||||
| SCI control | 61.80±9.41 | 0.27 | 61.80 | 1.89±0.18 | 1.61±0.23 | 8.78±0.55 | |||||||
| JIN[ | Intact | 0.30 | 0.3±0.00 | 0.00 | |||||||||
| Medium (control) | 3.63 | 3.8±0.90 | 0.17 | ||||||||||
| NPC transplant |
|
|
| ||||||||||
| NPC transplant with Chase/LV (N/C) |
|
|
| ||||||||||
| NPC transplant with Chase/LV+BDNF/NT-3/LV (N/C/G) |
|
|
| ||||||||||
P<0.05: Improvement of bladder function after stem cell transplantation or grafting. There was no quantitative information about the cystometric parameters in the text and the result was written based on figure information. BM-SCs: Bone marrow stromal cells; NPCs: Neural progenitor cells; Chase/LV: Lentiviral vector expressing chondroitinase; Chase/LV+BDNF/NT-3/LV: Lentiviral vector expressing chondroitinase and growth factor treatments, B10 cell: BM3.B10 (B10); hMSCs: Human mesenchymal stem cell; PBS: Phosphate-buffered saline; hFbs: Human fibroblasts